Terms ending in 2038
Every in-force patent on Boditech Med Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,693,019 | Automated Liquid-Phase Immunoassay Apparatus In force · High confidence | Boditech Med Inc. | In force | High confidence | |
| US 11,173,491 | Apparatus for High-Speed Nucleic Acid Amplification and Method for Temperature Control of Nucleic Acid Amplification Reaction In force · High confidence | U-GENE&CELL Co. and Boditech Med Inc. | In force | High confidence | |
| US 11,035,869 | Automated Liquid-Phase Immunoassay Apparatus In force · High confidence | Boditech Med Inc. | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.